Humacyte (HUMA) Total Current Liabilities (2020 - 2026)

Humacyte (HUMA) has reported Total Current Liabilities for 7 consecutive years, with $14.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 29.11% year-over-year to $14.9 million in Q2 2026; TTM through Jun 2026 was $14.9 million, a 29.11% decrease from a year earlier, with the FY2025 full-year figure at $18.4 million, down 7.93% from the prior year.
• Total Current Liabilities was $14.9 million for Q2 2026 at Humacyte, down from $16.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $25.6 million in Q3 2025 and troughed at $10.8 million in Q1 2022.
• A 5-year average of $17.6 million and a median of $18.1 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 7834.57% in 2022 and plunged 40.31% in 2024, its largest moves.
• Over 5 years, Total Current Liabilities stood at $19.6 million in 2022, then decreased by 5.81% to $18.4 million in 2023, then advanced by 8.19% to $20.0 million in 2024, then declined by 7.93% to $18.4 million in 2025, then fell by 18.64% to $14.9 million in 2026.
• The last three Total Current Liabilities figures came in at $14.9 million (Q2 2026), $16.2 million (Q1 2026), and $18.4 million (Q4 2025), per Business Quant data.